Estrogen Receptor and Cytokeratin 5 Are Reliable Markers to Separate Usual Ductal Hyperplasia From Atypical Ductal Hyperplasia and Low-Grade Ductal Carcinoma In Situ.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Archives of Pathology & Laboratory Medicine

• Publication date

  2016-04-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.5858/arpa.2015-0238-OAPMID 27116088
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Application of immunohistochemistry in breast pathology: a review and update.

  2014cited by this paper
• Use of immunohistochemistry in the diagnosis of problematic breast lesions

  2013cited by this paper
• Atypical ductal hyperplasia: interobserver and intraobserver variability

  2011cited by this paper
• Cytokeratin 5 and Estrogen Receptor Immunohistochemistry as a Useful Adjunct in Identifying Atypical Papillary Lesions on Breast Needle Core Biopsy

  2009cited by this paper
• Morphologic and Molecular Evolutionary Pathways of Low Nuclear Grade Invasive Breast Cancers and Their Putative Precursor Lesions: Further Evidence to Support the Concept of Low Nuclear Grade Breast Neoplasia Family

  2008cited by this paper
• The Role of Cytokeratin 5/6 as an Adjunct Diagnostic Tool in Breast Core Needle Biopsies

  2008cited by this paper
• Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.

  2007cited by this paper
• The value of p63 and CK5/6 expression in the differential diagnosis of ductal lesions of breast

  2006cited by this paper
• Relationship between nuclear grade of ductal carcinoma in situ and cell origin markers.

  2006cited by this paper
• Premalignant and In Situ Breast Disease: Biology and Clinical Implications

  2005cited by this paper
• Benign Breast Disease and Breast Cancer Risk: Morphology and Beyond

  2003cited by this paper
• The diagnosis and management of pre-invasive breast disease: Ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH) – current definitions and classification

  2003cited by this paper
• Molecular and Biologic Markers of Premalignant Lesions of Human Breast

  2002cited by this paper
• Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ

  2002cited by this paper
• Progesterone Receptor A and B Isoforms in the Human Breast and Its Disorders

  2001cited by this paper
• Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast

  2000cited by this paper
• Oestrogen receptor expression in the normal and pre‐cancerous breast

  1999cited by this paper
• Breast cancer risk associated with proliferative breast disease and atypical hyperplasia

  1993cited by this paper
• A comparison of the results of long‐term follow‐up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast

  1990cited by this paper
• Atypical hyperplastic lesions of the female breast. A long‐term follow‐up study

  1985cited by this paper
• Risk factors for breast cancer in women with proliferative breast disease.

  1985cited by this paper
• Intraductal carcinoma of the breast: Follow‐up after biopsy only

  1982cited by this paper

• [18F]Fluoroestradiol Uptake in Benign Nodular Sclerosing Adenosis of the Breast.

  2026cites this paper
• Overdiagnosis of breast malignancy: Azzopardi's Problems in Breast Pathology revisited, Part I.

  2025cites this paper
• Underdiagnosis of breast malignancy: Azzopardi's Problems in Breast Pathology revisited, part II.

  2025cites this paper
• Histological lesions of risk for breast carcinoma. An updated survival guide

  2025cites this paper
• Association between GPX4 and HMGCR gene expression and cell proliferation in atypical hyperplasia of the breast

  2024cites this paper
• Atypical Ductal Hyperplasia of the Breast: A Narrative Review

  2024cites this paper
• Spectrum of atypical ductal hyperplasia (ADH) and ductal carcinoma in-situ (DCIS): Diagnostic challenges.

  2024cites this paper
• Nontoxic Fluorescent Nanoprobes for Multiplexed Detection and 3D Imaging of Tumor Markers in Breast Cancer

  2023cites this paper
• Incorporation of exemestane into ternary nanosponge system for enhanced anti-tumor potential in breast cancer

  2023cites this paper
• Diagnostic Pitfalls in Breast Cancer Pathology With an Emphasis on Core Needle Biopsy Specimens.

  2023cites this paper
• Sclerosing Fibroadenoma With Atypical Ductal Hyperplasia Mimicking Invasive Carcinoma: A Case Report With Diagnostic Pitfall

  2023cites this paper
• Updates in the Use of Immunohistochemical Stains in Breast and Gynecologic Pathology.

  2023cites this paper
• The role of immunohistochemistry in diagnostic breast pathology

  2022cites this paper
• Atypia in breast pathology: what pathologists need to know.

  2021cites this paper
• Can High Molecular Weight Cytokeratin 903 Differentiate Benign Usual Breast Ductal Hyperplasia from Atypical Ductal Hyperplasia and Ductal Carcinoma in Situ? Report of a Case and Brief Review of the Literature

  2020cites this paper
• Patients with benign papilloma diagnosed on core biopsies and concordant pathology-radiology findings can be followed: experiences from multi-specialty high-risk breast lesion conferences in an academic center

  2020cites this paper
• Immunohistochemistry for diagnosis and prognosis of breast cancer: a review

  2020cites this paper
• [Histological lesions of risk of breast carcinoma. Survival guide for the general pathologist].

  2020cites this paper
• NordiQC Assessments of Keratin 5 Immunoassays

  2020cites this paper
• Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update.

  2019cites this paper
• Gene expression signature of atypical breast hyperplasia and regulation by SFRP1

  2019cites this paper
• Core needle biopsy of benign, borderline and in-situ problematic lesions of the breast: Diagnosis, differential diagnosis and immunohistochemistry.

  2019cites this paper
• Intraductal Proliferative Disease of the Breast

  2019cites this paper
• Atypical Ductal Lesions of the Breast: Criteria, Significance, and Laboratory Updates.

  2018cites this paper
• Usual Ductal Hyperplasia (UDH)

  2018cites this paper
• Non-classic LCIS Versus Classic LCIS Versus Atypical Hyperplasia: Should Management be the Same?

  2018cites this paper
• Assessing intraductal proliferations in breast core needle biopsies

  2018cites this paper
• New Developments in Breast Cancer and Their Impact on Daily Practice in Pathology.

  2017cites this paper